SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (461)2/3/2009 11:39:54 AM
From: ghmm  Read Replies (1) of 508
 
Does anyone have an idea of who would be more favorable to the data (as is with no further trial) EMEA or FDA? Any chance either would consider the Japanese data as a supportive trial or at best is it just seen as additional clinical data of some sort?

The replay is available (and so are slides).
Paul Noble points out this difference in sites:
80% US Cap-1 60% Cap-2 (which goes against the x-US being a problem argument.)

I believe it was Bradford who suggest there may be slight differences in enrolled patients to account for some of difference. So I would look for a bullish spin at ATS :)

EDIT Slides Link: phx.corporate-ir.net

EDIT again:
Slide 12 is VERY interesting I don't know why they didn't stress baseline FVC in Cap-1 Pirfenidone is 74.5 vs 70.3.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News